Interferon β for Multiple Sclerosis

Cold Spring Harbor Perspectives in Medicine

Volumn 8, Issue 11, 2018, Pages

  Jakimovski, Dejan ^a   Kolb, Channa ^a   Ramanathan, Murali ^a   Zivadinov, Robert ^a   Weinstock Guttman, Bianca ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; MACROGOL; PEGINTERFERON BETA1A;

DISEASE EXACERBATION; HUMAN; MEDICATION COMPLIANCE; METABOLISM; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BIOMARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; INTERFERON-BETA; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85053795017     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a032003     Document Type: Article

References (121)

1. Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, et al. 2016. Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: Benefits versus risks. Mult Scler Int 2016: 1034912.
2. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, et al. 2010. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 75: 1794–1802.
3. Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. 2014. Effect of peginterferon β-1a on MRI measures and achieving no evidence of disease activity: Results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol 14: 240.
4. Arnold D, You X, Shang S, Sperling B, Evilevitch V. 2015. Long-term efficacy in MRI and no evidence of disease activity outcomes in patients with relapsing-remitting multiple sclerosis treated with peginterferon β-1a. Neurology 84 (Suppl P7.266).
5. 1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon β-1b treatment. Brain 124: 1396–1402.
6. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al. 1992. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326: 581– 588.
7. Bendtzen K. 2003. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 61: S6–S10.
8. Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. 2010. Intramuscular interferon β-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study. Mult Scler 16: 588–596.
9. Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA. 2013. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol 73: 95–103.
10. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, et al. 2014. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol 13: 657–665.
11. Chadha K, Weinstock-Guttman B, Zivadinov R, Bhasi K, Muhitch J, Feichter J, Tamano-Blanco M, Abdelrahman N, Ambrus J Sr, Munschauer F, et al. 2006. Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol 63: 1579–1584.
12. Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. 2011. High-dose frequency β-interferons increase the risk of liver test abnormalities in multiple sclerosis: A longitudinal study. Mult Scler 17: 361–367.
13. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNβ-1a (Avonex) Dose-Comparison Study Investigators. 2002. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 59: 1507–1517.
14. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, et al. 2001. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58: 961–967.
15. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, et al. 2002. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 59: 679–687.
16. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402– 415.
17. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, et al. 2012. Alemtuzumab versus interferon β 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 380: 1819–1828.
18. Comi G, Barkhof F, Durelli L, Edan G, Fernandez O, Filippi M, Hartung HP, Hommes OR, Seeldrayers P, Soelberg-Sorensen P. 1995. Early treatment of multiple sclerosis with Rebif (recombinant human interferon β): design of the study. Mult Scler 1: S24–S27.
19. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, et al. 2001. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 357: 1576–1582.
20. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, et al. 2012. Comparison of two dosing frequencies of subcutaneous interferon β-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial. Lancet Neurol 11: 33–41.
21. Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, Marhardt K, Chen L, Issard D, Kappos L. 2017. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry 88: 285–294.
22. Cree B, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, et al. 2016. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80: 499–510.
23. Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. 2000. A comparative study of the relative bioavailability of different interferon β preparations. Neurology 54: 2055–2060.
24. De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, et al. 2014. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 85: 647–653.
25. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, et al. 2011. The Global Adherence Project (GAP): A multi-center observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18: 69–77.
26. Dhib-Jalbut S, Marks S. 2010. Interferon-β mechanisms of action in multiple sclerosis. Neurology 74: S17–S24.
27. Dujmovic I, Hegen H, Paz P, Croze E, Deisenhammer F. 2017. Persistency of neutralizing anti-interferon-β antibodies in patients with multiple sclerosis treated with subcutaneous interferon-β depends on antibody titers, IgG subclasses, and affinity maturation. J Interferon Cytokine Res 37: 317–324.
28. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M; Independent Comparison of Interferon Trial Study Group. 2002. Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359: 1453– 1460.
29. Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Wein-stock-Guttman B, et al. 2015. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon β-1a subcutaneously three times weekly: An open-label two-arm trial. BMC Neurol 15: 232.
30. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Nose-worthy JH. 2008. Disability as an outcome in MS clinical trials. Neurology 71: 624–631.
31. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study. 2009. Long-term follow-up of the original interferon-β-1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clin Ther 31: 1724–1736.
32. Edan G, Kappos L, Montalban X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, et al. 2014. Long-term impact of interferon β-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 85: 1183–1189.
33. Einarson TR, Bereza BG, Machado M. 2017. Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: A meta-analysis of real-world studies. Curr Med Res Opin 33: 579–593.
34. European Study Group on Interferon β-1b in Secondary Progressive MS. 1998. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon β-1b in secondary progressive MS. Lancet 352: 1491–1497.
35. Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F, Alsop J, Stam Moraga M, Kaplowitz N. 2003. Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a: Incidence and clinical significance. Drug Safety 26: 815–827.
36. Francis GS, Rice GP, Alsop JC, Group PS. 2005. Interferon β-1a in MS: Results following development of neutralizing antibodies in PRISMS. Neurology 65: 48–55.
37. Freedman MS. 2011. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 76: S26–S34.
38. Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L. 2014. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord 3: 147–155.
39. Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, et al. 2017. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord 12: 70–78.
40. Goodin DS. 2005. Treatment of multiple sclerosis with human β interferon. Int MS J 12: 96–108.
41. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSi-mone TM, et al. 2012a. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 78: 1315–1322.
42. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, et al. 2012b. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 83: 282–287.
43. Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L; European IFN-1a in Relapsing MS Dose Comparison Trial Study Group. 2005. Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a. Neurology 64: 236–240.
44. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, et al. 2016. Ocrelizumab versus interferon β-1a in relapsing multiple sclerosis. N Engl J Med 376: 221–234.
45. Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, et al. 2014. Early detection of neutralizing antibodies to interferon-β in multiple sclerosis patients: Binding antibodies predict neutralizing antibody development. Mult Scler 20: 577–587.
46. Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodri-guez-Bada JL, Leon A, Guerrero M, Fernandez O, Leyva L, Oliver-Martos B. 2017. Activation of the JAK-STAT signaling pathway after in vitro stimulation with IFNβ in multiple sclerosis patients according to the therapeutic response to IFNβ. PLoS ONE 12: e0170031.
47. Jacobs L, O’Malley J, Freeman A, Ekes R. 1981. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214: 1026–1028.
48. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. 1996. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285–294.
49. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. 2000. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898–904.
50. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F; European Study Group in Interferon β-1b in Secondary-Progressive MS. 2001. Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS. Neurology 57: 1969–1975.
51. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H; European (EUSPMS) Interferon β-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board, et al. 2004. Interferon β-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 63: 1779–1787.
52. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, et al. 2006a. Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242– 1249.
53. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, et al. 2006b. Long-term subcutaneous interferon β-1a therapy in patients with relapsing-remitting MS. Neurology 67: 944–953.
54. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Bauer L, et al. 2007. Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 370: 389–397.
55. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Metzig C, et al. 2009. Long-term effect of early treatment with interferon β-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8: 987–997.
56. Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, et al. 2016. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87: 978–987.
57. Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, et al. 2015. Peginterferon β-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 21: 1025–1035.
58. Kinkel RP, Kollman C, O’Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, et al. 2006. IM interferon β-1a delays definite mul- tiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678–684.
59. Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. 2012. Association between immediate initiation of intramuscular interferon β-1a at the time of a clinically isolated syndrome and long-term outcomes: A 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 69: 183–190.
60. Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, et al. 2016. A 10-year follow-up of the European multi-center trial of interferon β-1b in secondary-progressive multiple sclerosis. Mult Scler 22: 533–543.
61. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. 2013. The effects of long-term interferon-β-1b treatment on cognitive functioning in multiple sclerosis: A 16-year longitudinal study. Mult Scler 19: 1765–1772.
62. La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, Filippini G. 2012. Interferon β for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 1: CD005181.
63. Langdon D, Reder AT, Ebers G. 2007. EDSS and MRI burden of disease predict cognitive status at 16 years: Data from the long-term follow-up study. Mult Scler 13: S268–S269.
64. Langer-Gould A, Moses HH, Murray TJ. 2004. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 63: S35–S41.
65. Li D, Ebers G, Traboulsee A, Tam R, Goodin D, Konieczny A,2006. Interferon β-1b 16-year long-term follow-up study: MRI outcomes. Mult Scler 12: S188–S189.
66. Link J, Ramanujam R, Auer M, Ryner M, Hassler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, et al. 2017. Clinical practice of analysis of anti-drug antibodies against interferon β and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE 12: e0170395.
67. Magner WJ, Weinstock-Guttman B, Rho M, Hojnacki D, Ghazi R, Ramanathan M, Tomasi TB. 2016. Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. J Neuroimmunol 292: 68–78.
68. Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. 2013. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 19: S24–S40.
69. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. 1999. Effect of interferon-β-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-β-1b in Secondary Progressive Multiple Sclerosis. Ann Neurol 46: 850–859.
70. Minagar A, Murray TJ, Investigators PS. 2008. Efficacy and tolerability of intramuscular interferon β-1a compared with subcutaneous interferon β-1a in relapsing MS: Results from PROOF. Curr Med Res Opin 24: 1049–1055.
71. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. 2001. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 23: 125–132.
72. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, et al. 2000. The effect of interferon β-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis. Brain 123: 2256–2263.
73. Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, et al. 2009. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 66: 1345–1352.
74. Pachner AR, Dail D, Pak E, Narayan K. 2005. The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies. J Neuroimmunol 166: 180–188.
75. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinshenker B. 2002. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496–1506.
76. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon β-1b in Secondary Progressive MS. 2004. Interferon β-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 63: 1788–1795.
77. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O’Connor P, Li D, Weinshenker B; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy Study Group and EV the University of British Columbia MS/MRI Research Group. 2005. Benefits of high-dose, high-frequency interferon β-1a in re-lapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 239: 67–74.
78. Paty DW, Li DK. 1993. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43: 662–667.
79. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, et al. 2010. Recommendations for clinical use of data on neutralising antibodies to interferon-β therapy in multiple sclerosis. Lancet Neurol 9: 740– 750.
80. Pozzilli C, Pugliatti M, Paradig MSG. 2015. An overview of pregnancy-related issues in patients with multiple sclerosis. Eur J Neurol 22: 34–39.
81. PRISMS Study Group. 1998. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352: 1498– 1504.
82. PRISMS Study Group and the University of British Columbia. 2001. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56: 1628–1636.
83. Ransohoff RM. 1998. Cellular responses to interferons and other cytokines: The JAK-STAT paradigm. N Engl J Med 338: 616–618.
84. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study. 2010. Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS. Neurology 74: 1877–1885.
85. Reder AT, Oger JF, Kappos L, O’Connor P, Rametta M. 2014. Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord 3: 294–302.
86. Rio J, Rovira A, Tintore M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X. 2008. Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients. Mult Scler 14: 479– 484.
87. Rio J, Rovira A, Tintore M, Otero-Romero S, Comabella M, Vidal-Jordana A, Galan I, Castillo J, Arrambide G, Nos C, et al. 2017. Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Mult Scler doi: 10.1177/1352458517698052.
88. Rizzo F, Giacomini E, Mechelli R, Buscarinu MC, Salvetti M, Severa M, Coccia EM. 2016. Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol 94: 886–894.
89. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. 1999. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53: 1698–1704.
90. Rudick RA, Lee JC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, Hyde R, Zhang H, You X. 2010. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: Eight-year follow-up. Arch Neurol 67: 1329–1335.
91. Santos R, Weinstock-Guttman B, Tamano-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F III, Ramanathan M. 2006. Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies. J Neuroimmunol 176: 125–133.
92. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1: 457– 462.
93. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-β-1a in MSSG. 2001. Randomized controlled trial of interferon-β-1a in secondary progressive MS: Clinical results. Neurology 56: 1496–1504.
94. Signori A, Gallo F, Bovis F, Di Tullio N, Maietta I, Sormani MP. 2016. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord 6: 57–63.
95. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. 1998. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 43: 79–87.
96. Simon JH, Kinkel RP, Kollman C, O’Connor P, Fisher E, You X, Hyde R, CHAMPIONS Investigators Group CI. 2015. Ten-year follow-up of the “minimal MRI lesion” sub-group from the original CHAMPS Multiple Sclerosis Prevention Trial. Mult Scler 21: 415–422.
97. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, et al. 2003. Clinical importance of neutralising antibodies against interferon β in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184–1191.
98. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C; EFNS Task Force on Anti-IFN-β Antibodies in Multiple Sclerosis. 2005a. Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: Report of an EFNS task force on IFN-β antibodies in multiple sclerosis. Eur J Neurol 12: 817–827.
99. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group. 2005b. Appearance and disappearance of neutralizing antibodies during interferon-β therapy. Neurology 65: 33–39.
100. Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N. 2011. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 77: 1684–1690.
101. Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, et al. 2016. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology 87: 134–140.
102. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. 2011. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 28: 51–61.
103. The IFNB Multiple Sclerosis Study Group. 1993. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43: 655–661.
104. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: Experience during the first three years. Neurology 47: 889–894.
105. Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K. 2016. Interferon-β exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 22: 801–809.
106. Tremlett HL, Yoshida EM, Oger J. 2004. Liver injury associated with the β-interferons for MS: A comparison between the three products. Neurology 62: 628–631.
107. Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuiani A, Livrea P; Southern Italy MS Group. 2003. Interferon β in relapsing-remitting multiple sclerosis: An independent postmarketing study in southern Italy. Mult Scler 9: 451–457.
108. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, et al. 2007. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 61: 300–306.
109. Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, et al. 2016. Serum lipid profile changes predict neurode-generation in interferon-β-1a treated multiple sclerosis patients. J Lipid Res 58: 403–411.
110. Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, Tyblova M, Ramasamy D, Zivadinov R, Horakova D. 2017. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon β-1a treatment over long-term follow-up? Mult Scler 23: 242–252.
111. Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. 2011. Impact of exposure to interferon β-1a on outcomes in patients with relapsing-remitting multiple sclerosis: Exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 4: 3–14.
112. Vartanian T. 2003. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon β products in the treatment of multiple sclerosis. Clin Ther 25: 105–118.
113. Weiner HL. 2009. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol 65: 239–248.
114. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. 1989. The natural history of multiple sclerosis: A geographically based study. I: Clinical course and disability. Brain 112: 133–146.
115. Weinstock-Guttman B. 2013. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Am J Manag Care 19: s343–s354.
116. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, Baier M, Feichter J, Ramanathan M. 2003. Genomic effects of IFN-β in multiple sclerosis patients. J Immunol 171: 2694–2702.
117. Weinstock-Guttman B, Tamano-Blanco M, Bhasi K, Zivadinov R, Ramanathan M. 2007. Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients. J Neuroimmunol 182: 236–239.
118. Weinstock-Guttman B, Bhasi K, Badgett D, Tamano-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M. 2008. Genomic effects of once-weekly, intramuscular interferon-β 1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 205: 113–125.
119. Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O. 2008. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71: 136–144.
120. Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, et al. 2014. Effect of treatment with interferon β-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: A 24-week, controlled pilot study. PLoS ONE 9: e91098.
121. Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, Weinstock-Guttman B, Benedict RR, Vaneckova M, Barnett M, et al. 2016. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 16: 777–793.